The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have progressed on prior therapy.

Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response ...

A new research paper was published in Oncotarget's Volume 16 on January 20, 2025, titled "Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells." ...

Replimune Group Inc (NASDAQ: NASDAQ:REPL), a biotech firm focused on oncolytic immunotherapies, announced today that its Biologics License Application (BLA) for RP1 in combination with nivolumab has ...

PDUFA action date of July 22, 2025, with priority reviewWOBURN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the ...

The gut microbiome, or the community of microorganisms residing in the gastrointestinal tract, has emerged as an important ...

Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the ...

We offer a comprehensive suite of immune checkpoint-related products, including high-quality proteins, inhibitor screening ...

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, and Georgetown University's Lombardi Comprehensive Cancer Center today announced a collaboration to explore the ...

Georgia Tech researchers have developed biosensors with advanced sleuthing skills and the technology may revolutionize cancer ...

Researchers have discovered that mouse PD-1 is significantly weaker than human PD-1, calling into question their reliability ...

highlighting some of the strangest or craftily concealed contraband that passengers have tried to sneak through checkpoints. “You won’t believe what people brought to the airport,” the ...